395
Participants
Start Date
April 23, 2014
Primary Completion Date
September 20, 2015
Study Completion Date
July 17, 2024
Enzalutamide
Oral
Placebo
Oral
CN00103, Beijing
CN00104, Beijing
CN00106, Beijing
CN00111, Beijing
CN00112, Beijing
CN00114, Beijing
CN00115, Beijing
CN00127, Beijing
CN00121, Changsha
CN00107, Hangzhou
CN00110, Nanjing
CN00117, Nanjing
CN00102, Shanghai
CN00105, Shanghai
CN00108, Shanghai
CN00113, Shanghai
CN00126, Shanghai
CN00119, Suzhou
CN00125, Tianjin
CN00118, Wenzhou
CN00109, Wuhan
CN00124, Xi'an
HK00402, Hong Kong
KR00214, Anyang
KR00205, Busan
KR00207, Busan
KR00212, Cheongju-si
KR00203, Daegu
KR00213, Daejeon
KR00201, Incheon
KR00202, Seongnam-si
KR00204, Seoul
KR00206, Seoul
KR00208, Seoul
KR00209, Seoul
KR00210, Seoul
KR00211, Seoul
KR00215, Seoul
TW00309, Kaohsiung City
TW00302, Taichung
TW00303, Taichung
TW00307, Tainan City
TW00308, Tainan City
TW00301, Taipei
TW00304, Taipei
TW00306, Taipei
TW00305, Taoyuan
Lead Sponsor
Astellas Pharma Inc
INDUSTRY